KP-1461

Last updated
KP-1461
KP1461.svg
Clinical data
Drug class Reverse transcriptase inhibitor
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H23N4O6
Molar mass 367.382 g·mol−1
3D model (JSmol)
  • CCCCCCCOC(=O)NC1=NCN(C(=O)N1)[C@H]2C[C@@H]([C@H](O2)CO)O
  • InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1
  • Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS. [1] It belongs to the class of nucleoside reverse transcriptase inhibitors. [2]

KP-1461 is a prodrug of the active antiviral agent KP-1212. [3]

References

  1. ↑ "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
  2. ↑ Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1) S13. doi: 10.1186/1742-4690-3-S1-S13 . PMC   1716920 .
  3. ↑ "KP-1461". DrugBank. Canadian Institutes of Health Research.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.